Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab plus irinotecan versus irinotecan in relapsed or refractory small cell lung cancer
2017-000758-20Phase 2Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Apr 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in small cell lung cancer (SCLC) comparing Dinutuximab plus irinotecan with Irinotecan (2 arms). Primary endpoint: overall survival. Started Apr 2017; status: completed.
02
Drugs
dinutuximabirinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2017-000758-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000758-20.